1
/
of
1
Pemtero (Pemetrexed)
Pemtero (Pemetrexed)
Regular price
₱18,000.00 PHP
Regular price
Sale price
₱18,000.00 PHP
Taxes included.
Quantity
Couldn't load pickup availability
Pemtero (Pemetrexed) is a potent multitargeted antifolate chemotherapy agent specifically indicated for treating locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. As a prescription-only oncology medication, Pemtero works by inhibiting critical folate-dependent enzymatic pathways—thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase—that cancer cells depend on for DNA and RNA synthesis and proliferation.
Pemetrexed is administered intravenously as part of combination chemotherapy regimens, frequently paired with platinum-based agents such as cisplatin. It has become a cornerstone of first-line and maintenance therapy in advanced NSCLC across multiple histologies, offering superior efficacy compared to single-target antifolate agents. Oncologists and specialized cancer care teams prescribe Pemtero for patients with advanced-stage malignancies where surgical resection or radiation therapy are not feasible treatment modalities.
This chemotherapy agent demonstrates efficacy in improving survival outcomes and disease progression metrics in eligible patient populations. The multitargeted mechanism provides broader anti-cancer activity, making it a preferred choice within comprehensive oncology treatment strategies. Clinical efficacy extends across diverse NSCLC phenotypes and represents a standard therapeutic option in modern cancer medicine.
Dosing of Pemtero requires individualized adjustments based on renal function, ECOG performance status, and baseline hematologic parameters. Premedication protocols include folic acid and vitamin B12 supplementation to mitigate hematologic and gastrointestinal toxicity and optimize clinical tolerability. Administration occurs exclusively in monitored clinical or hospital settings with appropriate oncology nursing oversight and supportive care infrastructure.
Pemtero is available through licensed pharmacy distribution channels and is restricted to use under direct physician supervision in accredited oncology practices. This product represents a critical therapeutic resource for advanced lung malignancy and mesothelioma management, delivering evidence-based outcomes in eligible patient populations requiring systemic chemotherapy intervention.
Pemetrexed is administered intravenously as part of combination chemotherapy regimens, frequently paired with platinum-based agents such as cisplatin. It has become a cornerstone of first-line and maintenance therapy in advanced NSCLC across multiple histologies, offering superior efficacy compared to single-target antifolate agents. Oncologists and specialized cancer care teams prescribe Pemtero for patients with advanced-stage malignancies where surgical resection or radiation therapy are not feasible treatment modalities.
This chemotherapy agent demonstrates efficacy in improving survival outcomes and disease progression metrics in eligible patient populations. The multitargeted mechanism provides broader anti-cancer activity, making it a preferred choice within comprehensive oncology treatment strategies. Clinical efficacy extends across diverse NSCLC phenotypes and represents a standard therapeutic option in modern cancer medicine.
Dosing of Pemtero requires individualized adjustments based on renal function, ECOG performance status, and baseline hematologic parameters. Premedication protocols include folic acid and vitamin B12 supplementation to mitigate hematologic and gastrointestinal toxicity and optimize clinical tolerability. Administration occurs exclusively in monitored clinical or hospital settings with appropriate oncology nursing oversight and supportive care infrastructure.
Pemtero is available through licensed pharmacy distribution channels and is restricted to use under direct physician supervision in accredited oncology practices. This product represents a critical therapeutic resource for advanced lung malignancy and mesothelioma management, delivering evidence-based outcomes in eligible patient populations requiring systemic chemotherapy intervention.
Share
